SAN DIEGO, May 29, 2018 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies will
participate in two upcoming investor conferences.
Dr. Helen Torley, president and
chief executive officer will represent Halozyme in a question and
answer session at the Goldman Sachs 39th Annual Global
Healthcare Conference in Rancho Palos
Verdes on Tuesday, June 12 at
6:20 p.m. ET / 3:20 p.m. PT.
On Wednesday, June 20,
Laurie Stelzer, senior vice
president and chief financial officer will represent Halozyme in a
question and answer session at the 2018 JMP Securities Life
Sciences Conference in New York at
2:30 p.m. ET / 11:30 a.m. PT.
Webcasts of both sessions can be accessed through the
"Investors" section of www.halozyme.com, and a recording will be
made available for 90 days following each event. To access a live
webcast, please visit Halozyme's website approximately 15 minutes
prior to the presentation to register and download any necessary
audio software.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug
pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to
targeting solid tumors, allowing increased access of
co-administered cancer drug therapies to the tumor in animal
models. PEGPH20 is currently in development for metastatic
pancreatic cancer, non-small cell lung cancer, gastric cancer,
metastatic breast cancer and has potential across additional
cancers in combination with different types of cancer therapies. In
addition to its proprietary product portfolio, Halozyme has
established value-driving partnerships with leading pharmaceutical
companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly,
Bristol-Myers Squibb and Alexion for its ENHANZE® drug
delivery technology. Halozyme is headquartered in San Diego. For more information visit
www.halozyme.com.
Contacts:
Jim
Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-participate-in-upcoming-healthcare-conferences-300655885.html
SOURCE Halozyme Therapeutics, Inc.